CLINICAL TRIALS PROFILE FOR PINDOLOL

All Clinical Trials for PINDOLOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00149110 ↗	Chronos: the Use of Chronobiological Treatment in Depression	Completed	Eli Lilly and Company	N/A	2005-09-01	The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise.
NCT00149110 ↗	Chronos: the Use of Chronobiological Treatment in Depression	Completed	The County of Frederiksborg	N/A	2005-09-01	The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise.
NCT00149110 ↗	Chronos: the Use of Chronobiological Treatment in Depression	Completed	Hillerod Hospital, Denmark	N/A	2005-09-01	The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise.
NCT00159146 ↗	Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression	Terminated	Tvergaards Foundation	N/A	2002-08-01	This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine.

Clinical Trial Conditions for PINDOLOL

Condition Name

Condition Name for PINDOLOL
Intervention	Trials
Major Depression	3
Major Depressive Disorder	2
Cardiac Failure	2
Healthy	2

Condition MeSH

Condition MeSH for PINDOLOL
Intervention	Trials
Depressive Disorder	7
Depression	6
Depressive Disorder, Major	5
Heart Failure, Diastolic	2

Clinical Trial Locations for PINDOLOL

Trials by Country

Trials by Country for PINDOLOL
Location	Trials
United States	17
Denmark	4
Switzerland	2
Spain	2
United Kingdom	1

Trials by US State

Trials by US State for PINDOLOL
Location	Trials
New York	3
Florida	2
California	2
North Carolina	1
Maryland	1

Clinical Trial Progress for PINDOLOL

Clinical Trial Phase

Clinical Trial Phase for PINDOLOL
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	3
Phase 3	1

Clinical Trial Status

Clinical Trial Status for PINDOLOL
Clinical Trial Phase	Trials
Completed	7
Terminated	4
Enrolling by invitation	2

Clinical Trial Sponsors for PINDOLOL

Sponsor Name

Sponsor Name for PINDOLOL
Sponsor	Trials
Actimed Therapeutics Ltd	2
University Hospital, Basel, Switzerland	2
Hillerod Hospital, Denmark	2

Sponsor Type

Sponsor Type for PINDOLOL
Sponsor	Trials
Other	26
Industry	9
NIH	4

Clinical Trials Update, Market Analysis and Projection for Pindolol

Last updated: April 24, 2026

What is pindolol’s current clinical development position?

Pindolol (non-selective beta-adrenoceptor blocker with intrinsic sympathomimetic activity and partial 5-HT1A/5-HT1B receptor activity) is an established generic medicine. Clinical activity today is dominated by (1) small pharmacokinetic, formulation, and bioequivalence studies, (2) use in investigator-initiated trials in defined clinical questions, and (3) periodic regulatory/label-maintenance work rather than late-stage, pipeline-changing development.

Clinical trials signals (public registries)

Across major registries, pindolol trials are sparse relative to modern investigational cardiovascular and CNS programs. When pindolol appears, the study designs are typically early-stage, observational, or comparative bioavailability work rather than phase-2 or phase-3 efficacy expansion. This profile is consistent with a drug whose primary commercial role is off-patent use and generic supply.

What phases are most common?

The most visible trial categories for pindolol in public records are:

• Bioequivalence / formulation / pharmacokinetic (PK) studies (common for generic launches and changes in manufacturing sites or dosage forms)
• Small, investigator-led clinical studies (often repurposing or targeting specific physiologic endpoints)
• Limited late-stage efficacy trials (few, and typically not driving near-term market re-rating)

Implication for investors and R&D: the market is not dependent on a single “new pivotal program.” Growth is driven by baseline demand for beta-blockade products, plus substitution effects between generics, fixed-dose combinations where present in local markets, and manufacturing scale and compliance.

---

What is the global market context for pindolol?

Market reality: off-patent generic beta-blocker

Pindolol is widely available as a generic beta-blocker. The commercial market structure is:

• Competitive pricing
• High SKU fragmentation by strength, dosage form, and local regulatory approvals
• Tender and hospital formularies driving volume more than premiumization

Category framing: beta-blockers

Pindolol sits inside the broader beta-blocker class. Beta-blockers are a mature global therapeutic area with sustained demand due to chronic cardiovascular indications and high baseline prevalence. Within that mature category, pindolol competes against multiple beta-blockers that dominate share in many geographies (for example metoprolol, bisoprolol, propranolol, atenolol). Pindolol’s relative share trends with:

• Local prescribing norms
• Availability and reimbursement
• Formulary decisions
• Supply chain pricing dynamics among generic manufacturers

---

Where does demand come from?

Pindolol’s demand typically maps to label and off-label use patterns in cardiovascular care. The most repeatable demand drivers are:

• Stable hypertension and related outpatient cardiovascular indications
• Angina prophylaxis and symptomatic management in appropriate patients
• Arrhythmia or rate-control use where guideline-concordant and locally favored
• Use in specific clinical protocols in some settings (varies by country)

Because pindolol is generic, demand is less a function of incremental clinical evidence and more a function of procurement and prescribing habits.

---

What is the market outlook for pindolol (next 5 years)?

Projection approach

For an established generic beta-blocker, the most reliable forward view is:

• Volume trend: stable to modest growth aligned with underlying cardiovascular incidence and patient retention on chronic therapy
• Price trend: continued downward pressure from generic competition
• Net revenue trend: typically low single-digit CAGR or flattish dynamics in many markets unless manufacturing capacity, tender wins, or regional substitution shifts favor a subset of suppliers

Base-case market projection (directional)

Using the typical maturity profile of generic cardiovascular small molecules:

• Global volume: low to mid single-digit growth
• Net sales (value): flat to low growth in many regions due to price erosion offsetting incremental volume

Time horizon: 2026 to 2031.

Upside and downside levers

Upside levers

• Expansion in markets where pindolol remains on formularies and reimbursement lists
• Manufacturing scale improvements that win tender pricing
• Increased use of fixed-dose combinations or alternative dosage forms where available

Downside levers

• Continued physician shift toward more commonly stocked beta-blockers (bisoprolol/metoprolol class dominance in many formularies)
• Further price compression from additional generic entries
• Regulatory tightening that increases cost of supply and reduces eligible manufacturers

---

What does this mean for R&D priorities?

Given the drug’s off-patent status, the dominant R&D-economic logic is not a de novo brand-new efficacy program, but one of:

• Formulation improvements that reduce cost or improve adherence
• Regulatory maintenance to keep market access friction low
• PK/PD optimization studies that support label variations in specific regions
• Niche investigator-led studies only where there is a clear clinical endpoint and sponsor alignment

For market entrants, the economic path is procurement and distribution scale rather than late-stage clinical differentiation.

---

Clinical trial pipeline summary for pindolol

What to look for in the next 24 months

If you are monitoring clinical updates that can move commercial expectations, the signals are:

• New bioequivalence studies tied to specific manufacturers or dosage strengths
• Any country-specific phase or protocol that changes label text (rare for this mature drug)
• Any evidence-led regulatory reformulation path (for example extended-release where applicable)

In practice, trial volume in registries is more likely to reflect generic lifecycle management than a new therapeutic standard of care.

---

Key Takeaways

• Pindolol’s clinical development today is dominated by small PK, formulation, and bioequivalence studies typical of off-patent generic medicines rather than phase-2/phase-3 efficacy expansion.
• The market is structurally mature and price-competitive; growth is mainly volume-driven with persistent value pressure from generic competition.
• Over 2026 to 2031, the most likely pattern is stable to modest global volume growth with flat-to-low single-digit net sales growth, unless tender wins or regional formulary shifts favor specific suppliers.
• Commercial leverage comes from manufacturing scale, regulatory continuity, and distribution/formulary access rather than new pivotal clinical evidence.

---

FAQs

1) Is pindolol still undergoing major phase 3 development?

Public signals in major registries are consistent with limited late-stage efficacy development, with most visible activity focused on bioequivalence, PK, and smaller investigator-led studies.

2) What drives market share for pindolol in practice?

Tender pricing, formulary inclusion, reimbursement status, and day-to-day prescribing habits determine supplier volume more than novel clinical differentiation.

3) How should investors think about revenue growth for an off-patent beta-blocker?

Expect volume stability to modest growth and persistent price compression. Net sales typically track underlying demand with low value CAGR unless distribution wins or mix shifts occur.

4) Are clinical trial updates likely to change pindolol’s market trajectory?

Unlikely in most cases. Trial updates are more often lifecycle management (generics) than label-changing evidence.

5) What R&D directions have the highest probability of commercial impact?

Formulation and regulatory lifecycle work that reduces supply cost, improves adherence, or secures/maintains access in specific markets.

---

References

[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA Approved Drug Products (Drug Details for pindolol, where available). https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. (n.d.). Medicine details for pindolol (where available). https://www.ema.europa.eu/
[3] ClinicalTrials.gov. (n.d.). Search results for pindolol (clinical studies). https://clinicaltrials.gov/
[4] World Health Organization. (n.d.). WHO Model Lists of Essential Medicines (beta-blockers context). https://www.who.int/teams/health-product-and-policy-standards/essential-medicines
[5] Drugs.com. (n.d.). Pindolol (information on indications and usage). https://www.drugs.com/